Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | Ceritinib | ALK | RTK | 0.34376 | -0.6157 | 0.4566 | 0.1487 | 0.9502 | 0.88109 | 0.9932 |
| MDA-MB-231 | Tivantinib | MET | RTK | 0.41694 | -0.0845 | 0.3330 | 0.1029 | 2.2640 | 0.43275 | 0.99134 |
| Hs 578T | Cabozantinib | VEGFR2/MET | RTK | 6.3728 | 0.2155 | 0.1335 | 0.0452 | 1.3885 | 14.0588 | 0.89112 |
| MCF 10A | Cabozantinib | VEGFR2/MET | RTK | 25.9104 | 0.8434 | -0.0114 | 0.0040 | 4.9998 | 11.7694 | 0.81226 |
| MCF7 | Cabozantinib | VEGFR2/MET | RTK | 4.8819 | -0.0993 | 0.1069 | 0.0302 | 1.8080 | 8.9638 | 0.99698 |
| MDA-MB-231 | Neratinib | EGFR/HER2 | RTK | 1.4329 | -0.0957 | 0.1056 | 0.0516 | 1.6284 | 2.8124 | 0.99527 |
| Hs 578T | Ceritinib | ALK | RTK | 0.96543 | -0.4356 | 0.3052 | 0.1254 | 0.8330 | 3.6097 | 0.98175 |
| Hs 578T | Cediranib | VEGFR/cKIT | RTK | 0.55083 | -0.5723 | 0.3937 | 0.1358 | 0.6641 | 2.8803 | 0.96002 |
| MCF 10A | Neratinib | EGFR/HER2 | RTK | 0.10243 | 0.0959 | 0.3443 | 0.0215 | 1.1138 | 0.081751 | 0.99316 |
| MCF 10A | Cediranib | VEGFR/cKIT | RTK | 9.6397 | 0.4781 | 0.0310 | 0.0012 | 3.3546 | 8.1 | 0.99825 |
| MCF7 | Tivantinib | MET | RTK | 0.1513 | -0.0512 | 0.4534 | 0.0984 | 1.7693 | 0.15446 | 0.99667 |
| MCF7 | Cediranib | VEGFR/cKIT | RTK | 5.7041 | 0.1149 | 0.0758 | 0.0191 | 1.5383 | 11.6508 | 0.98993 |
| HCC1806 | Cediranib | VEGFR/cKIT | RTK | 4.9315 | 0.0954 | 0.0645 | 0.0363 | 4.9998 | 4.7786 | 0.98723 |
| MDA-MB-231 | Ceritinib | ALK | RTK | 0.86565 | -0.3326 | 0.3444 | 0.1014 | 1.9065 | 1.1609 | 0.99581 |
| HCC1806 | Cabozantinib | VEGFR2/MET | RTK | 11.367 | 0.6905 | -0.0025 | 0.0050 | 4.9955 | 13.3217 | 0.89668 |
| HCC1806 | Ceritinib | ALK | RTK | 2.1149 | -0.4060 | 0.1766 | 0.0793 | 2.2387 | 2.8712 | 0.99364 |
| Hs 578T | Neratinib | EGFR/HER2 | RTK | 0.6444 | -0.1608 | 0.2025 | 0.0665 | 0.8744 | 2.2637 | 0.98743 |
| Hs 578T | Tivantinib | MET | RTK | 0.33668 | -0.3204 | 0.4411 | 0.2071 | 2.0560 | 0.42597 | 0.99878 |
| HCC1806 | Tivantinib | MET | RTK | 0.27161 | -0.2185 | 0.4464 | 0.1810 | 3.1555 | 0.30267 | 0.99849 |
| MCF 10A | Ceritinib | ALK | RTK | 2.9867 | -0.3186 | 0.1843 | 0.0521 | 1.3962 | 6.5603 | 0.98775 |
| HCC1806 | Neratinib | EGFR/HER2 | RTK | 0.77903 | -0.0883 | 0.1927 | 0.0757 | 0.8116 | 3.0161 | 0.95894 |
| MCF 10A | Tivantinib | MET | RTK | 0.18116 | -0.1502 | 0.4509 | 0.1498 | 2.3782 | 0.1918 | 0.99221 |
| MCF7 | Neratinib | EGFR/HER2 | RTK | 1.2629 | 0.0582 | 0.1421 | 0.0220 | 1.0034 | 3.7746 | 0.97694 |
| MDA-MB-231 | Cabozantinib | VEGFR2/MET | RTK | 4.8325 | 0.0749 | 0.1413 | 0.0336 | 1.2384 | 11.7338 | 0.95871 |
| MDA-MB-231 | Cediranib | VEGFR/cKIT | RTK | 5.0964 | -0.3620 | 0.1160 | 0.0659 | 2.7537 | 7.595 | 0.99835 |